Induction of severe systemic lupus erythematosus by TNF blockade and response to anti-IL-6 strategy

Journal of Allergy and Clinical Immunology

Volumn 131, Issue 4, 2013, Pages 1235-1237.e1

  Adler, Sabine ^a   Kolev, Mirjam ^a   Varisco, Pierre Alain ^a   Tham, Manuela ^a   Von Gunten, Michael ^a   Tappeiner, Christoph ^a   Villiger, Peter M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; HLA DR2 ANTIGEN; HLA DR3 ANTIGEN; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; METHYLPREDNISOLONE; MUSCLE ENZYME; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR;

AGED; AUTOIMMUNE DISEASE; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEVER; GRANULOMA; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRIDOCYCLITIS; LETTER; LEUKOPENIA; MALE; MITRAL VALVE REGURGITATION; MUSCLE NECROSIS; PERICARDITIS; POLYARTHRITIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84875729559     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2012.09.034     Document Type: Article

References (10)

1. W. Kievit, E.M. Adang, J. Fransen, H.H. Kuper, M.A. van de Laar, and T.L. Jansen The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data Ann Rheum Dis 67 2008 1229 1234
2. G. Jones, A. Sebba, J. Gu, M.B. Lowenstein, A. Calvo, and J.J. Gomez-Reino Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Ann Rheum Dis 69 2010 88 96
3. K. Steenland, and D.F. Goldsmith Silica exposure and autoimmune diseases Am J Ind Med 28 1995 603 608
4. G.C. Parks, G.S. Cooper, L.A. Nylander-French, W.T. Sanderson, J.M. Dement, and P.L. Cohen Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the Southeastern United States Arthritis Rheum 46 2002 1840 1850 (Pubitemid 34774516)
5. L. Josselin, A. Mahr, P. Cohen, C. Pagnoux, G. Guaydier- Souquières, and G. Hayem Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients Ann Rheum Dis 67 2008 1343 1346
6. F. Atzeni, A. Doria, M. Carrabba, M. Turiel, and P. Sarzi-Puttini Potential target of infliximab in autoimmune and inflammatory diseases Autoimm Rev 6 2007 529 536 (Pubitemid 47374618)
7. K. Ohl, and K. Tenbrock Inflammatory cytokines in systemic lupus erythematosus J Biomed Biotech 2011 2011 432595
8. P.M. Villiger, and L. Guillevin Microscopic polyangiitis: clinical presentation Autoimmun Rev 9 2010 812 819
9. E.L. Williams, S. Gadola, and C.J. Edwards Anti-TNF-induced lupus Rheumatology (Oxford) 48 2009 716 720
10. G.G. Illei, Y. Shirota, C.H. Yarboro, J. Daruwalla, E. Tackey, and K. Takada Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study Arthritis Rheum 62 2010 542 552